Figure 6
Figure 6. Efficacy of NVP-AST487 in mice bearing mutant FLT3-expressing cells. (A) Time to onset of morbidity in mutant FLT3-Ba/F3–harboring athymic nude mice treated with vehicle or NVP-AST487 (30 mg/kg, or “low-dose”) or NVP-AST487 (50 mg/kg, or “high-dose”). (B) Mouse photos show bioluminescence of mice following 6 days after intravenous injection. B708, C711, and D718 are NMP/PEG300 vehicle controls for NVP-AST487–treated mice. B709, D720, and E725 are vehicle controls for PKC412-treated mice. (C,D) Bioluminescence values graphed for treatment groups. Error bars represent SEM.

Efficacy of NVP-AST487 in mice bearing mutant FLT3-expressing cells. (A) Time to onset of morbidity in mutant FLT3-Ba/F3–harboring athymic nude mice treated with vehicle or NVP-AST487 (30 mg/kg, or “low-dose”) or NVP-AST487 (50 mg/kg, or “high-dose”). (B) Mouse photos show bioluminescence of mice following 6 days after intravenous injection. B708, C711, and D718 are NMP/PEG300 vehicle controls for NVP-AST487–treated mice. B709, D720, and E725 are vehicle controls for PKC412-treated mice. (C,D) Bioluminescence values graphed for treatment groups. Error bars represent SEM.

Close Modal

or Create an Account

Close Modal
Close Modal